Skip to content
value.today

Opyn Health, Inc.

Total raised
$57 M
6 rounds on record
Latest round
$5 M
Sep 2025
First round on record
Dec 2017
Today
Private
No later event on record

Funding rounds

6 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Opyn Health, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$1 MIssued in a merger or acquisitionUnder $2 million

Opyn Health, Inc.: Private sale, Oct 2025

Investors in this round

1 investor had bought by the notice of Sep 3, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard Fuchs · Executive Officer, Director
  • Courtney Faith Paulson · Director
  • Ian McBane · Director
  • Jon Freshman · Director
  • Munawar Ali · Director
  • Stuart Peterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “10/14/2025 Issuer purchase of Empara LLC equity securites, Issuer issued Goodroot, LLC, Empara's parent, 1,000,000 shares of !ssuer's Series D Preferred Stock. If conditions met, Issuer will issue Goodroot 2nd quarter 2027 up to 888,896 Series D shares.”

Signed by Richard A. Fuchs, Ceo. Newest notice filed Sep 3, 2026. Read the notice at the SEC.

equitySEC
Sep 2025$5 MNo. 6$2 to $10 million

Opyn Health, Inc.: Raise no. 6, Sep 2025

Investors in this round

12 investors had bought by the notice of Sep 3, 2026: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered; $1 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$37,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard Fuchs · Executive Officer, Director
  • Courtney Faith Paulson · Director
  • Ian McBane · Director
  • Jon Freshman · Director
  • Munawar Ali · Director
  • Stuart Peterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Odeon Capital Group LLC (CRD 148493) · New York, New YorkSold in all US states

Signed by Richard A. Fuchs, Ceo. Newest notice filed Sep 3, 2026. Read the notice at the SEC.

debt, optionsSEC
Mar 2024$7 MNo. 5$2 to $10 million

Opyn Health, Inc.: Raise no. 5, Mar 2024

Investors in this round

11 investors had bought by the notice of Apr 15, 2024: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $20 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Louis DiGiovine · Executive Officer
  • Ian McBane · Director
  • Kimberly Tzoumakas · Director
  • Munawar Ali · Director
  • Stuart Peterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Odeon Capital Group (CRD 000148493) · New York, New YorkSold in all US states

Signed by Louis DiGiovine, SVP and Chief Financial Officer. Newest notice filed Apr 15, 2024. Read the notice at the SEC.

debt, optionsSEC
Feb 2023$1 MNo. 4Under $2 million

Opyn Health, Inc.: Raise no. 4, Feb 2023

Investors in this round

0 investors had bought by the notice of Mar 23, 2023: 0 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $15 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$750,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Louis DiGiovine · Executive Officer
  • David Klein · Director
  • Ian McBane · Director
  • Kim Tzoumakas · Director
  • Munawar Ali · Director
  • Stuart Peterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Odeon Capital Group LLC (CRD 148493) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Fee equal to 5% cash of gross proceeds”

Signed by Louis DiGiovine, SVP, Finance & Chief Financial Officer. Newest notice filed Mar 23, 2023 (1 amendment). Read the notice at the SEC.

debt, optionsSEC
Oct 2020$28 MNo. 3$10 to $50 million

Opyn Health, Inc.: Raise no. 3, Oct 2020

Investors in this round

28 investors had bought by the notice of Feb 10, 2021: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$28 M of $30 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,350,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl Smith · Executive Officer
  • David Klein · Director
  • Ian McBane · Director
  • Jason Beans · Director
  • Kim Tzoumakas · Director
  • Munawar Ali · Director
  • Robert Mortensen · Director
  • Stuart Peterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Odeon Capital Group LLC (CRD 148493) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Fee equal to 6.0% cash and 3.0% in Series C Preferred for gross proceeds of up to $12.5 million, and 5.0% and 2.0% in cash and stock, respectively, for amounts in excess of $12.5 million. The fee amount listed assumes the offering is fully subscribed.”

Signed by Carl Smith, Senior Vice President, Finance. Newest notice filed Feb 10, 2021 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
Nov 2019$10 MNo. 2$2 to $10 million

Opyn Health, Inc.: Raise no. 2, Nov 2019

Investors in this round

36 investors had bought by the notice of Jan 2, 2020: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $12 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Mayhall · Executive Officer
  • David Klein · Director
  • Gerald Ostrov · Director
  • Ian McBane · Director
  • Jason Beans · Director
  • Jonathan Palmer · Director
  • Munawar Ali · Director
  • Robert Mortensen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Odeon Capital Group LLC (CRD 148493) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Equals 10.0% of gross proceeds from offering with (i) 7.0% payable in cash, and (ii) 3.0% payable in Issuer's Series B Preferred Stock and accompanying warrants.”

Signed by James Mayhall, President. Newest notice filed Jan 2, 2020 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
Dec 2017$6 MNo. 1$2 to $10 million

Opyn Health, Inc.: Raise no. 1, Dec 2017

Investors in this round

23 investors had bought by the notice of Oct 30, 2018: 21 accredited, 2 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $11 M offered; $5 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$770,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Limited Liability Company, incorporated in Florida

People named in the notice

  • Eric R. Hanson · Director
  • Gerald R. Ostrov · Director
  • Ian R. McBane · Director
  • Jason R. Beans · Director
  • Jonathan R. Palmer · Director
  • Munawar R. Ali · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Odeon Capital Group, LLC (CRD 148493) · broker-dealer Odeon Capital Group, LLC (CRD 148493) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “Equals 10% of gross proceeds from the offering with (i) 7.0% payable in cash, and (ii) 3.0% payable in the Company's Series A Preferred Units.”

Signed by Jonathan Palmer, Lead Independent Director. Newest notice filed Oct 30, 2018 (2 amendments). Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Opyn Health, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Sep 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Opyn Health, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Opyn Health, Inc.
NameRoleNamed in
Richard FuchsExecutive officerSep 2026
Louis DiGiovineExecutive officerApr 2024
Carl SmithExecutive officerFeb 2021
James MayhallExecutive officerNov 2020
Courtney Faith PaulsonDirectorSep 2026
Ian McBaneDirectorSep 2026
Jon FreshmanDirectorSep 2026
Munawar AliDirectorSep 2026
Richard FuchsDirectorSep 2026
Stuart PetersonDirectorSep 2026
Kimberly TzoumakasDirectorApr 2024
David KleinDirectorMar 2023
Kim TzoumakasDirectorMar 2023
Jason BeansDirectorFeb 2021
Robert MortensenDirectorFeb 2021
Gerald OstrovDirectorJan 2020
Jonathan PalmerDirectorJan 2020
Eric R. HansonDirectorOct 2018
Gerald R. OstrovDirectorOct 2018
Ian R. McBaneDirectorOct 2018
Jason R. BeansDirectorOct 2018
Jonathan R. PalmerDirectorOct 2018
Munawar R. AliDirectorOct 2018
Alexander R. FraserDirectorMay 2018
Peter R. BaronoffDirectorMay 2018